Copyright © Accurexa Inc.  All rights reserved.

UCSF: University of California, San Francisco, GDNF: Glial Derived Neurotrophic Factor

Our Pipeline

We are focused on effective and safe, targeted delivery of therapies, e.g. the direct delivery of chemotherapeutics to brain tumor sites in order to overcome the limitations of the blood-brain barrier.  We are currently developing a diversified pipeline in collaborations with universities and other Biotech companies.  


  • ACX-31 local chemotherapy wafer developed for the treatment of brain cancer in collaboration with Johns Hopkins University
  • Combination of ACX-31 wafer with a PARP inhibitor in development (AstraZeneca's and Clovis Oncology's PARP inhibitors already approved)
  • Collaboration with DelMar Pharmaceuticals to develop the ACX-31 wafer in combination with DelMar's VAL-083 small molecule chemotherapeutic for the treatment of brain cancer